# Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

> **NCT04522050** · PHASE1 · UNKNOWN · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 65 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Gemcitabine combined with cisplatin induction chemotherapy
- **DRUG:** concurrent chemoradiotherapy with gemcitabine

## Key facts

- **NCT ID:** NCT04522050
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522050, "Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04522050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*